Myriad Genetics, Inc. (MYGN) Holdings Boosted by Moors & Cabot Inc.

Moors & Cabot Inc. boosted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 33.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,475 shares of the company’s stock after purchasing an additional 5,375 shares during the period. Moors & Cabot Inc.’s holdings in Myriad Genetics were worth $557,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. raised its stake in Myriad Genetics by 168,335.7% during the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after purchasing an additional 9,536,219 shares during the period. Vanguard Group Inc. raised its stake in Myriad Genetics by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock worth $162,992,000 after purchasing an additional 56,708 shares during the period. Camber Capital Management LLC raised its stake in Myriad Genetics by 6.5% during the first quarter. Camber Capital Management LLC now owns 4,325,000 shares of the company’s stock worth $83,040,000 after purchasing an additional 265,000 shares during the period. Dimensional Fund Advisors LP raised its stake in Myriad Genetics by 29.8% during the second quarter. Dimensional Fund Advisors LP now owns 3,430,216 shares of the company’s stock worth $88,636,000 after purchasing an additional 787,396 shares during the period. Finally, Thrivent Financial For Lutherans raised its stake in Myriad Genetics by 7,026.7% during the second quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock worth $70,862,000 after purchasing an additional 2,703,860 shares during the period.

Several equities research analysts have recently issued reports on the stock. Morgan Stanley reissued an “underweight” rating and issued a $24.00 price objective (up previously from $17.00) on shares of Myriad Genetics in a research report on Friday. Leerink Swann reissued a “market perform” rating and issued a $31.00 price objective on shares of Myriad Genetics in a research report on Monday, October 2nd. Stephens reissued an “overweight” rating and issued a $40.00 price objective (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Cowen and Company reissued a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a research report on Sunday, September 17th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $24.18.

Myriad Genetics, Inc. (MYGN) traded up 0.19% during midday trading on Tuesday, reaching $36.69. 42,673 shares of the company were exchanged. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $37.30. The firm’s 50-day moving average is $32.90 and its 200-day moving average is $25.15. The firm has a market cap of $2.51 billion, a P/E ratio of 115.02 and a beta of 0.27.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. During the same quarter last year, the firm posted $0.36 earnings per share. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities analysts expect that Myriad Genetics, Inc. will post $1.03 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Myriad Genetics, Inc. (MYGN) Holdings Boosted by Moors & Cabot Inc.” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/10/myriad-genetics-inc-mygn-holdings-boosted-by-moors-cabot-inc.html.

In other news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the transaction, the director now owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 6.20% of the company’s stock.

Myriad Genetics Profile

Myriad

A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. raised its stake in Myriad Genetics by 168,335.7% during the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after purchasing an additional 9,536,219 shares during the period. Vanguard Group Inc. raised its stake in Myriad Genetics by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock worth $162,992,000 after purchasing an additional 56,708 shares during the period. Camber Capital Management LLC raised its stake in Myriad Genetics by 6.5% during the first quarter. Camber Capital Management LLC now owns 4,325,000 shares of the company’s stock worth $83,040,000 after purchasing an additional 265,000 shares during the period. Dimensional Fund Advisors LP raised its stake in Myriad Genetics by 29.8% during the second quarter. Dimensional Fund Advisors LP now owns 3,430,216 shares of the company’s stock worth $88,636,000 after purchasing an additional 787,396 shares during the period. Finally, Thrivent Financial For Lutherans raised its stake in Myriad Genetics by 7,026.7% during the second quarter. Thrivent Financial For Lutherans now owns 2,742,340 shares of the company’s stock worth $70,862,000 after purchasing an additional 2,703,860 shares during the period.

Several equities research analysts have recently issued reports on the stock. Morgan Stanley reissued an “underweight” rating and issued a $24.00 price objective (up previously from $17.00) on shares of Myriad Genetics in a research report on Friday. Leerink Swann reissued a “market perform” rating and issued a $31.00 price objective on shares of Myriad Genetics in a research report on Monday, October 2nd. Stephens reissued an “overweight” rating and issued a $40.00 price objective (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Cowen and Company reissued a “hold” rating and issued a $25.00 price objective on shares of Myriad Genetics in a research report on Sunday, September 17th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $23.00 price objective (up previously from $21.00) on shares of Myriad Genetics in a research report on Thursday, August 10th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $24.18.

Myriad Genetics, Inc. (MYGN) traded up 0.19% during midday trading on Tuesday, reaching $36.69. 42,673 shares of the company were exchanged. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $37.30. The firm’s 50-day moving average is $32.90 and its 200-day moving average is $25.15. The firm has a market cap of $2.51 billion, a P/E ratio of 115.02 and a beta of 0.27.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The company had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. During the same quarter last year, the firm posted $0.36 earnings per share. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities analysts expect that Myriad Genetics, Inc. will post $1.03 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Myriad Genetics, Inc. (MYGN) Holdings Boosted by Moors & Cabot Inc.” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/10/myriad-genetics-inc-mygn-holdings-boosted-by-moors-cabot-inc.html.

In other news, Director John T. Henderson sold 30,000 shares of Myriad Genetics stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $30.30, for a total value of $909,000.00. Following the transaction, the director now owns 52,524 shares of the company’s stock, valued at $1,591,477.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 6.20% of the company’s stock.

Myriad Genetics Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply